Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Panel To Weigh Relevance Of Liraglutide’s Diabetes Experience In Obesity

This article was originally published in The Pink Sheet Daily

Executive Summary

Agency will ask external advisors Sept. 11 how the GLP-1 agonist’s safety in type 2 diabetes, approved as Victoza in 2010, informs the safety profile in obesity, where Novo Nordisk is seeking a higher dose and a different name.

Advertisement

Related Content

At Liraglutide Panel Review, A Call For CV Studies To Look Beyond MACE
Novo Nordisk’s Liraglutide Gets Panel Nod For Weight Management
Novo Nordisk’s Liraglutide Gets Panel Nod For Weight Management
Orexigen’s Big Plans On Hold As FDA Hashes Out Post-Marketing Requirements
FDA Clears Victoza, But Warnings And More Studies Pose Hurdles

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS077752

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel